SERPIND1

(redirected from HC-II)

SERPIND1

A gene on chromosome 22q11.21 that encodes a member of the serine protease inhibitor (serpin) family that rapidly inhibits thrombin in the presence of dermatan sulfate or heparin. SERPIND1 shares homology with antithrombin III and other members of the alpha 1-antitrypsin superfamily.

Molecular pathology
SERPIND1 mutations are associated with heparin cofactor-II deficiency.
References in periodicals archive ?
In the US, the current HC-II test retails for about US$22 per test, takes 6-7 h to process, and requires access to laboratory equipment and a computer (36).
Patients, in whom conventional cytology, HC-II test and colposcopy-directed biopsy were done, formed the basis of this study.
Interpretation & conclusion: The main utility of HC-II is in the triage of patients with cytology smear diagnosis of ASC-US, ASC-H or L-SIL, for referral to colposcopic examination.
The study population was restricted to high risk individuals for more focused application and more meaningful evaluation of HC-II.
Patients were called again for biopsy when either cytology report or HC-II was positive, if biopsy had not already been performed.
Specimen for HC-II was obtained in the same sitting, immediately after making the conventional cytology smear, using a conical brush and a vial containing the specimen transport medium (STM), both obtained from the manufacturer of HC-II (Digene Corporation, Maryland, USA).
HPV testing was done using HC-II assay (Digene Corporation, Maryland, USA) following the manufacturer's instructions.
HC-II testing: High-risk HPV infection was seen in 25 patients (18.
This selective screening method was adopted to increase the yield of positive cases; so that the utility of HC-II could be evaluated without unnecessarily increasing the sample size.
HC-II has been studied as a modality for screening of carcinoma cervix and has been shown to have high sensitivity but low specificity, reported as 100 and 85.
The main role of HC-II is in triage of patients having abnormal cytology smears since high cost prevents utility as a general screening technique.